Abiopharma

🔍 Armes Joseph B (Director)

Company: CSW INDUSTRIALS, INC. (CSW)

Report Date: 2026-08-14

Detailed Transactions and Holdings:

• Sold 1,500 shares of Common Stock at $345.1574 per share (Direct)
  Date: 2026-08-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 64,236.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-14 | Code: H | nature_of_ownership: by ESOP | shares_owned_after: 3,219.00
• Holds 9,836 shares of Performance Rights (Derivative)
  Date: 2026-08-14 | Code: H | shares_owned_after: 9,836.00 | Footnotes: F3, F3, F3
• Holds 8,004 shares of Performance Rights (Derivative)
  Date: 2026-08-14 | Code: H | shares_owned_after: 8,004.00 | Footnotes: F4, F4, F4
• Holds 8,236 shares of Performance Rights (Derivative)
  Date: 2026-08-14 | Code: H | shares_owned_after: 8,236.00 | Footnotes: F5, F5, F5
• Holds 9,186 shares of Performance Rights (Derivative)
  Date: 2026-08-14 | Code: H | shares_owned_after: 9,186.00 | Footnotes: F6, F6, F6
• Holds 19,685 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-14 | Code: H | shares_owned_after: 19,685.00 | Footnotes: F7, F7, F7

Footnotes:

• F1: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 12, 2025.
• F2: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $342.75 to $346.71, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
• F3: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 250% during a three-year performance cycle beginning on April 1, 2026 and ending on March 31, 2029 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.
• F4: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2025, and ending on March 31, 2028, based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.
• F5: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2024, and ending on March 31, 2027, based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.
• F6: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200%, during a performance cycle beginning April 1, 2021 and ending on March 31, 2027 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.
• F7: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at vesting. 40% of the restricted stock units vest no earlier than April 26, 2025 upon the successful recruitment and hiring of a successor Chief Executive Officer; the remaining 60% vest upon the successful first employment anniversary of a successor Chief Executive Officer.